Childhood Cancer Survivor Study Analysis Concept Proposal - Draft 11/19/2010

Title: Longitudinal changes in health care utilization by survivors of childhood cancer

1. <u>Working Group Investigators</u>: This proposed study will be within the Cancer Control Committee. The investigators include:

mit estigators me		
Jackie Casillas*	jcasillas@mednet.ucla.edu	310-794-0969
Paul Nathan**	paul.nathan@sickkids.ca	416-813-8795
Kevin Oeffinger	oeffingk@mskcc.org	212-639-8649
Melissa Hudson	Melissa.hudson@stjude.org	901-495-3445
Mark Greenberg	mark.greenberg@sickkids.ca	416-813-5886
Mark Yeazel	yeazel@umn.edu	612-624-2335
Kirsten Ness	kiri.ness@stjude.org	901-595-5157
Leslie Robison	les.robison@stjude.org	901- 595-3384
Greg Armstrong	greg.armstrong@stjude.org	901-595-5892
Wendy Leisenring	wleisenr@fhcrc.org	206-667-4374
Yutaka Yasui***	yyasui@ualberta.ca	780-492-4220

* Denotes 1st author; ** Denotes senior author; ***Denotes lead statistician for proposal.

2. Background and Rationale

The improved survival of children with cancer to almost 80% is one of the major success stories in oncology.¹ Consequently, there are over 328,000 childhood cancer survivors alive in the U.S.² This has resulted in an increasing number of adult survivors who require ongoing medical care and surveillance targeted at the chronic health problems that can arise from their cancer treatment (i.e. late effects) as well as ongoing health maintenance.^{3 4} Risk adapted follow-up care is essential for adult survivors of childhood cancer since more than two-thirds will develop a late effect and 25% will develop a severe or life-threatening late effect, such as cardiac or pulmonary disease, or a second malignancy.^{5 6} Since risk for late effects increases as survivors age, an understanding of the factors that influence health care utilization is vital in order to guide the development of interventions that can increase compliance with recommended risk-based care.

Two CCSS publications have examined the medical care reported by adult survivors of childhood cancer. The first presented cross sectional data from the baseline survey.⁷ The 9,434 respondents reported on four types of medical care received in the preceding two years. These categories were not mutually exclusive. Eighty-seven percent reported general or non-specific contact with a healthcare provider, 71% reported a general physical examination, 42% reported a cancer-related medical visit, and 19% reported a medical visit to a cancer center. This analysis generated four primary findings: (1) almost 90% of survivors report some contact with the medical system; (2) the likelihood of a general physical examination or a cancer-related medical visit decreases with age and time from diagnosis; (3) less than 20% of survivors are seen regularly in a cancer center; and (4) most survivors do not report care related to their prior cancer. The 2003 survey examined risk-based medical care in greater detail. In the publication arising from this survey, the medical care received by 8,522 survivors over the preceding two years was classified hierarchically into four mutually exclusive categories - 11% reported no medical care, 57% reported general medical care (a medical visit unrelated to their prior cancer), 14% reported general survivor-focused medical care (a medical visit related to their prior cancer) and 18% reported risk-based survivor-focused medical care (a medical visit related to their prior cancer in which screening tests were discussed or ordered or the survivor was counseled on how to reduce his/her specific risks).⁸ Consistent with the baseline study, most survivors (89%) reported some contact with the medical system; however, less than one-third reported an encounter related to their prior cancer, and less than one out of five survivors reported a visit in which their health care provider discussed ways to reduce the risks arising from their prior cancer treatment.

The CCSS has not formally examined the changes in healthcare utilization that have occurred longitudinally between the baseline, 2003 and 2007 surveys. Over that period, several factors may have increased compliance with regular cancer-focused medical care. For example, during the period between surveys, there has been a distribution of a biannual newsletter amongst participants in the CCSS.⁹ The Children's Oncology Group Survivorship Guidelines were published in 2003 which could also impact on health care utilization for long-term childhood cancer survivors.¹⁰ In addition, since the prevalence of late effects increases as survivors grow older, it is anticipated that the need for medical care focused on detecting or treating these late effects should increase. However, an informal look at data from the two CCSS publications reveals a concerning trend: the frequency of cancer-related medical visits (42% vs. 32%) and of visits to a cancer center (19% vs. 15%) decreased between the baseline and 2003 surveys. In essence, as risk increases, risk-based care appears to decrease. Lastly, during the proposed interval of our longitudinal analysis, Oeffinger and colleagues conducted an intervention study (Project VISION) which tested the feasibility of using a virtual information center to improve mammogram and echocardiographic screening in Hodgkin lymphoma survivors. This group may have improved health care utilization due to the one page treatment summary intervention, however, the sample size for this study was only 69 participants.¹¹

In the present analysis, we aim to examine longitudinal changes in cancer-related care utilization patterns since baseline enrollment. We intend to examine the patient- and disease-related factors that are associated with changes in health care patterns over time and identify factors associated with increased or decreased levels of cancer-related care. We are primarily interested in the receipt of "cancer-related care" (defined as a medical visit related to the prior cancer, or one in which the survivor is counseled about how to reduce their risks or has surveillance tests ordered or discussed). We would like to examine: (1) factors that predict an increased utilization cancer-related care (from a lower level, e.g. no health care); and (2) factors that predict a decrease in utilization of cancer-related (no longer receiving cancer-related care as reported at baseline). Although we will assess all predictive factors (i.e. demographic, socio-economic, disease/treatment, co-morbidities, etc), the clinical relevance will come from identifying modifiable predictors of change that we can target for future intervention research.

In summary, the clinical questions to be answered with this analysis are:

(1) What are the factors that predict survivors who received "cancer-related care at baseline and who are no longer receiving this level of care at a later time period (based on 2003, 2007 survey data)?(2) What are the factors that predict survivors who were not receiving "cancer-related care" at baseline and who are receiving this level of care at a later time period?

3. Specific Aims:

Specific Aim #1: To describe the changes in health care utilization by adult survivors of childhood cancer by comparing the medical care reported at the baseline questionnaire to that reported at follow-up (using 2003 and 2007 survey data) using the definitions of health care utilization described in the two previous CCSS publication on health care utilization.^{7 8}

Specifically, we will categorize medical care into one of three mutually exclusive levels. (1) *No health care*

(2) General medical care (one or more visits to a doctor or nurse, none of which were related to their prior cancer)

(3) *Cancer-related care* (defined as a medical visit related to the prior cancer, or one in which the survivor is counseled about how to reduce their risks or has surveillance tests ordered or discussed).

The 4th category, *risk-based survivor focused care*, described in the most recent health care utilization publication by Nathan et al will not be included as it cannot be generated from the data collected in the baseline survey. However, as this publication points out, the hierarchy we are using was "constructed to classify levels of medical care related specifically to the prior cancer and its risks and is not intended to imply a level of

quality of care for health issues unrelated to the previous cancer." In addition, "the assigned level of care is independent of who delivered the care (cancer specialist or primary care clinician) or where the care was received (cancer center or community setting)."⁸

We will describe the proportion of survivors who fall within a total of nine combinations of longitudinal care at baseline and at last point of contact (either 2003 or 2007) within 3 categories of change in health care utilization:

Category I = no change in level of health care utilization over time

- 1. No health care to no health care.
- 2. General medical care to general medical care.
- 3. Cancer-related care to cancer-related care.

Category II = increased level of health care utilization over time

- 4. No health care to general medical care.
- 5. No health care to cancer-related care.
- 6. General medical care to cancer-related care.

Category III = decreased level of health care utilization over time

- 7. General medical care to no health care.
- 8. Cancer-related care to general medical care.
- 9. Cancer-related care to no health care.

We will also describe the location of care received for survivors at baseline and at last point in contact (either 2003 or 2007). We will divide the survivors into groups who were seen:

- 1. At least once at a cancer center (regardless of who else they saw)
- 2. Seen at a doctor's office (but not a cancer center)
- 3. Never seen

Specific Aim #2: To determine the predictors of change in those survivors who report a decreased level of health care utilization between the baseline survey and a later time point.

Hypothesis: Socioeconomic variables (age, race/ethnicity, insurance status, income, education, employment status), health status variables, and treatment will be important predictors of having a decreased level of health care utilization between baseline and follow-up. More specifically, we hypothesize that being younger at the follow-up period (18-29 years), being a minority, being uninsured, having a lower income, having a lower educational achievement (< high school), and being unemployed will be predictive of having a decreased level of cancer care. In addition, having a good health status, having no pain, having good emotional health and having a lower chronic disease status burden will also be predictive of having a decreased level of cancer care over time.

<u>Specific Aim #3:</u> To determine the predictors of change in those survivors who report an increased level of health care utilization between the baseline survey and a later time point.

Hypothesis: Socioeconomic variables (age, race/ethnicity, insurance status, income, education, employment status, health status variables, and treatment will be important predictors of having an increased level of cancer care utilization between baseline and of follow-up. More specifically, we hypothesize that being older (\geq 30 years of age), being non-Hispanic white (NHW), being insured, having a higher income, having higher educational achievement (> high school), being employed will be predictive of having an increased level of cancer care. In addition, reporting a poorer health status, having pain, having poor emotional health and

having a higher chronic disease status burden will also be predictive of having an increased level of cancer care.

4. Methods for each specific aim as outlined below:

<u>Specific Aim #1:</u> We will complete an exploratory, descriptive analysis of the percent of survivors who fall within the 3 different combinations of the 3 major categories of change as described below. We will develop a 3 x 3 table of proportions (based on combinations of responses from baseline and follow-up). The full 9 category grid will be displayed descriptively in a table and will be illustrated in a graph.

Category I = no change in level of health care utilization over time

- 1. No health care to no health care.
- 2. General medical care to general medical care.
- 3. Cancer-related care to cancer-related care.

Category II = increased level of health care utilization over time

- 4. No health care to general medical care.
- 5. No health care to cancer-related care.
- 6. General medical care to cancer-related care.

Category III = decreased level of health care utilization over time

- 7. General medical care to no health care.
- 8. Cancer-related care to general medical care.
- 9. Cancer-related care to no health care.

We will also describe the location of care received for survivors at baseline and at last point in contact (either 2003 or 2007). We will divide the survivors into groups who were seen:

- 1. At least once at a cancer center (regardless of who else they saw)
- 2. Seen at a doctor's office (but not a cancer center)
- 3. Never seen

The data will be displayed descriptively in a table.

Specific Aim #2: To determine the predictors of change in those survivors who report a decreased level of cancer-related care utilization between the baseline survey and follow-up

<u>Subjects included in this analysis</u>: Survivors who received cancer-related care at baseline and have either or both of 2003 and 2007 surveys.

<u>Analysis framework</u>: We will look at whether they are receiving cancer-related care at the most recent follow ups (Yes/No). If the survivor responded to both the 2003 and 2007 questionnaires and their cancer-related care status is discordant between the two follow ups, we will use the 2007 follow up.

<u>Statistical model</u>: We will model the predictors of the change in cancer-related care, among those who were receiving it at baseline but were no longer receiving it at follow-up. Log-binomial models will be used to associate the probability of the change with covariates. Time since diagnosis at baseline will be included as a covariate: this will allow us to characterize change by groups defined by time from diagnosis to baseline (i.e., 10-yr, 15-yr, 20-yr, 25-yr survivors at baseline). In addition, all the covariates hypothesized or targeted due to their clinical relevance/modifiability will be assessed in the modeling.

<u>Result format</u>: We will present relative risk of no longer receiving cancer-related care at follow-up. The relative risk will be modeled by time since diagnosis and other clinically-relevant and/or modifiable characteristics at baseline.

<u>Utility</u>: We will know, among survivors who are receiving cancer-related care, the risk of no longer receiving cancer-related care at the follow-up time point based on the characteristics of the survivors.

<u>Specific Aim #3</u> To determine the predictors of change in those survivors who report an increased level of cancer-related care utilization between the baseline survey and follow-up.

We will complete the same analysis as 1, but analyze "survivors who were *not* receiving cancer-related care at baseline and report receiving such care at the last point of contact.

Other Statistical Considerations:

- 1. We will identify those survivors who participated into Project VISION and integrate receipt of the one page treatment summary intervention into the models as this can affect their utilization of care.
- 2. Inclusion Criteria:
 - All cancer diagnostic groups
 - Complete treatment information from medical record abstraction.
 - Alive at baseline and 2003 or 2007. We have chosen to use either or both the 2003 and 2007
 - participants as our analysis will be looking at changes from baseline to last point of contact.

3. Exclusion Criteria:

We will exclude the participants who died between baseline and 2003 or 2007 questionnaire, recognizing that we will need to include in our discussion of the results. We recognize that this analysis will not take into account the most severely affected survivors (those who are deceased) which can impact on the generalizability of our findings. However, we will show this mortality data in flow diagram to provide a clear picture of who is in the sample. Death rates are 1% per year and this is steady rate, i.e. a large number of survivors will not die at all once.

Data on the deceased reviewed for this concept proposal are (data from Yutaka Yasui): At baseline, there were 6,941 users of cancer care & 6,571 nonusers (definitions based on Oeffinger et al paper).⁷

Of the 6,941 baseline users, we have:

- 2258 32.5% non-users at FU2 (i.e. 2003)
- 1862 26.8% users at FU2
- 1318 19.0% died before FU2
- 1503 21.7% LTFU/Refused/missing cancer-care answer

Of the 6,571 baseline non-users, we have:

- 3532 53.8% non-users at FU2
- 922 14.0% users at FU2
- 292 4.4% died before FU2
- 1825 27.8% LTFU/Refused/missing cancer-care answer

Comment [mmh1]: Other survivor may have a treatment summary, so I assume that this will be considered for all in the model?

Sample Table	1:	Demographic.	diagnosis and	treatment	variables:

Age		Total n (%)	Baseline Questionnaire	2003 or 2007 Questionnaire	p-value
At time of questionnaire Age at dingnosis (mean) Age at dingnosis Charter at the set of	Ago		n (%)	n (%)	
Age at diagnosis (mean) Male Penale Male Penale Race/Ethnicity Non-Hispanic White (NHW) Black Hispanic Asian Other Health Insurance status No, U.S. Yes, U.S. Private Private Public Canadian resident Annual household income < \$40,000					
Gender					
Male Female RaceRthnicity Non-Hispanic White (NHW) Black Hispanic Asian Other Health Insurance status No, U.S. Yes, U.S. Private Public Canadian resident Annual household income < \$40,000					
Female Race/Ethnicity Non-Hispanic White (NHW) Black Black Hispanic Asian Other Health Insurance status <					
Race/Ethnicity					
Non-Hispanic White (NHW) Black Hispanic Asian Other Health Insurance status No, U.S. Yes, U.S. Yes, U.S. Private Public Canadian resident Annual household income < \$40,000 \$40-79,000 \$40,70,000 \$40,					
Black Asian					
Hispanic Asian Other Asian Other Hispanic Asian Other Health Insurance status No, U.S. Private					
Asian Other Carlos Constraints of the second					
Other Health Insurance status No, U.S. Private Private Pablic Canadian resident Annual household income < \$40,000					
Health Insurance status No, U.S. Yes, U.S. Private Public Canadian resident Annual household income < \$40,000					
No, U.S. Yes, U.S. Private Public Canadian resident					
Yes, U.S. Private Public Canadian resident Annual household income < \$40,000 \$40-79,000 \$40-79,000 \$40-79,000 \$40-79,000 \$40-79,000 S40-79,					
Private Public Canadian resident					
Public					
Canadian resident Annual household income < \$40,000					
Annual household income < \$40,000					
\$40.000 \$40.79,000 \$80,000 or greater Education < high school					
\$40-79,000 \$80,000 or greater \$ 80,000 or greater \$ <b< td=""><td></td><td></td><td></td><td></td><td></td></b<>					
\$80,000 or greater					
Education < high school					
<high p="" school<=""> High school</high>	Education				
High school					
College graduate					
Employment status Employed or caring for home Looking for work or unable to work Student Cancer diagnosis Leukemia CNS tumor Hodgkin lymphoma Non-Hodgkin lymphoma Wilms tumor Neuroblastoma Sarcoma Bone tumor Treatment variables Radiation therapy Brain Chest Not brain, not chest None RT status not known Cardiotoxic therapies Anthracyclines, no chest RT Anthracyclines, no chest RT No anthracyclines Anthracyclines, no chest RT Alkylating agent dose None 1 st tertile 2 ^{std} tertile					
Looking for work or unable to work	Employment status				
Student					
Student	Looking for work or unable to work				
Leukemia CNS tumor Hodgkin lymphoma Non-Hodgkin lymphoma Non-Hodgkin lymphoma Wilms tumor Neuroblastoma Sarcoma Bone tumor Treatment variables Radiation therapy Brain Chest Not brain, not chest None RT status not known Cardiotoxic therapies Anthracyclines, no chest RT Chest RT, no anthracyclines Anthracyclines + chest RT No anthracyclines, no chest RT Nonet RT No anthracyclines, no chest RT Alkylating agent dose None 1 st tertile 2 ^{rdt} tertile					
CNS tumor Hodgkin lymphoma Non-Hodgkin lymphoma Wilms tumor Non-Hodgkin lymphoma Wilms tumor Wilms tumor Sarcoma Sarcoma Sarcoma Bone tumor Treatment variables Radiation therapy Brain Chest Chest Not brain, not chest None RT status not known Cardiotoxic therapies Anthracyclines, no chest RT Chest RT, no anthracyclines Anthracyclines, no chest RT No anthracyclines, no chest RT None 1 st tertile 1 st tertile 2 nd tertile	Cancer diagnosis				
Hodgkin lymphoma Image: status not known Non-Hodgkin lymphoma Image: status not known Sarcoma Image: status not known Bone tumor Image: status not known Chest RT, no anthracyclines Anthracyclines + chest RT Image: status not known Chest RT, no anthracyclines Anthracyclines, no chest RT Image: status not known Chest RT, no anthracyclines Anthracyclines + chest RT Image: status not known Chest RT, no anthracyclines Anthracyclines + chest RT Image: status not known Alkylating agent dose Image: status not known None Image: status not known Alter T Chest RT, no anthracyclines Anthracyclines + chest RT Image: status not known Alkylating agent dose Image: status not known None Image: status not known Cardiotoxic therapies Image: status not known Cardiotoxic therapies Image: status not known Chest RT, no anthracyclines Anthracyclines + chest RT Image: status not known Alkylating agent dose Image: status not known None Image: status not known Image: status not known Cardiotoxic therapies Image: status not known Image: status not known Mone	Leukemia				
Non-Hodgkin lymphoma Wilms tumor Neuroblastoma Sarcoma Bone tumor Treatment variables Radiation therapy Brain Chest Not brain, not chest None RT status not known Cardiotoxic therapies Anthracyclines, no chest RT Chest RT, no anthracyclines Anthracyclines, no chest RT No anthracyclines, no chest RT No anthracyclines, no chest RT None 1 st tertile 1 st tertile 2 nd tertile	CNS tumor				
Wilms tumor Neuroblastoma Sarcoma Sarcoma Bone tumor Image: Constraint of the constr	Hodgkin lymphoma				
Neuroblastoma Sarcoma Sarcoma Bone tumor Treatment variables Image: Constraint of the constraint of th	Non-Hodgkin lymphoma				
Sarcoma Bone tumor Treatment variables Radiation therapy Brain Chest Not brain, not chest None RT status not known Cardiotoxic therapies Anthracyclines, no chest RT Chest RT, no anthracyclines Anthracyclines + chest RT No anthracyclines, no chest RT Alkylating agent dose None 1 st	Wilms tumor				
Bone tumor Image: constraint of the second seco					
Treatment variables Radiation therapy Brain Chest Not brain, not chest None RT status not known Cardiotoxic therapies Anthracyclines, no chest RT Chest RT, no anthracyclines Anthracyclines, no chest RT No anthracyclines, no chest RT No anthracyclines, no chest RT No anthracyclines, no chest RT If tertile 1 st tertile 2 nd tertile					
Radiation therapy Image: Second S	Bone tumor				
Brain Chest Not brain, not chest None RT status not known Cardiotoxic therapies Anthracyclines, no chest RT Chest RT, no anthracyclines Anthracyclines + chest RT No anthracyclines, no chest RT Alkylating agent dose None 1 st tertile 2 nd tertile					
Chest Not brain, not chest None Image: Chest RT status not known RT status not known Image: Chest RT status not known Cardiotoxic therapies Image: Chest RT status not known Anthracyclines, no chest RT Image: Chest RT status not known Chest RT, no anthracyclines Image: Chest RT status not known No anthracyclines, no chest RT Image: Chest RT status not known No anthracyclines, no chest RT Image: Chest RT status not known No anthracyclines, no chest RT Image: Chest RT status not known None Image: Chest RT status not known 1 st tertile Image: Chest RT status not known 2 nd tertile Image: Chest RT status not known					
Not brain, not chest Image: Cardiotoxic therapies RT status not known Image: Cardiotoxic therapies Cardiotoxic therapies Image: Cardiotoxic therapies Anthracyclines, no chest RT Image: Chest RT, no anthracyclines Chest RT, no anthracyclines Image: Cardiotoxic therapies Anthracyclines, no chest RT Image: Cardiotoxic therapies No anthracyclines, no chest RT Image: Cardiotoxic therapies Alkylating agent dose Image: Cardiotoxic therapies None Image: Cardiotoxic therapies 1 st tertile Image: Cardiotoxic therapies 2 nd tertile Image: Cardiotoxic therapies					
None RT status not known Cardiotoxic therapies Image: Cardiotoxic therapies Anthracyclines, no chest RT Image: Chest RT, no anthracyclines Chest RT, no anthracyclines Image: Chest RT No anthracyclines, no chest RT Image: Chest RT Alkylating agent dose Image: Chest RT None Image: Chest RT 1 st tertile 2 nd tertile Image: Chest RT					
RT status not known Image: Cardiotoxic therapies Cardiotoxic therapies Image: Cardiotoxic therapies Anthracyclines, no chest RT Image: Cardiotoxic therapies Chest RT, no anthracyclines Image: Cardiotoxic therapies Anthracyclines + chest RT Image: Cardiotoxic therapies No anthracyclines, no chest RT Image: Cardiotoxic therapies Alkylating agent dose Image: Cardiotoxic therapies None Image: Cardiotoxic therapies 1 st tertile 2 nd tertile					
Cardiotoxic therapies Image: Cardiotoxic therapies Anthracyclines, no chest RT Image: Chest RT Chest RT, no anthracyclines Image: Chest RT Anthracyclines + chest RT Image: Chest RT No anthracyclines, no chest RT Image: Chest RT Alkylating agent dose Image: Chest RT None Image: Chest RT 1 st tertile 2 nd tertile					
Anthracyclines, no chest RT Chest RT, no anthracyclines Anthracyclines + chest RT No anthracyclines, no chest RT Alkylating agent dose None 1 st tertile 2 nd tertile					
Chest RT, no anthracyclines Anthracyclines + chest RT No anthracyclines, no chest RT Alkylating agent dose None 1 st 1 st tertile 2 nd tertile					
Anthracyclines + chest RT No anthracyclines, no chest RT Alkylating agent dose None 1 st tertile 2 nd tertile					
No anthracyclines, no chest RT Alkylating agent dose None 1 st tertile 2 nd tertile					
Alkylating agent dose None 1 st tertile 2 nd tertile					
None 1 st tertile 2 nd tertile	No anthracyclines, no chest RT				
1 st tertile 2 nd tertile	Alkylating agent dose				
2 nd tertile					
2 tertile	1 st tertile				
	2 rd tertile 3 rd tertile				

Sample Table 2: Descriptive Statistics of Cancer-Related Care Utilization Changes between Baseline and last follow-up (either 2003, 2007 data):

Health Care Utilization Change	n
	(%)
Category I = no change in level of health care	
utilization over time	
No health care to no health care	
General medical care to general medical care	
Cancer-related care to cancer-related care	
Category II = increased level of health care	
utilization over time	
No health care to general medical care.	
No health care to cancer-related care.	
General medical care to cancer-related care.	
Category III = decreased level of health care	
utilization over time	
General medical care to no health care.	
Cancer-related care to general medical care.	
Cancer-related care to no health care	

Sample Table 3: Location of Care

	Baseline (Question B2)	Follow-Up (2003 – Question A2; 2007 - Question B2
Cancer Center		
Doctor's office, not Cancer Center		
None of the above, not seen		

variables as they change from B	aseline to the last time point of foll Baseline	2003 Questionnaire	2007 Questionnaire
Overall Health Status	N15	El	L19
Overall Health Status	Would you say your health is:	My health is excellent:	In general, would you say your
	- Excellent	- Definitely true	health is:
	- Very good	- Mostly true	- Excellent
	- Good	- Don't know	- Very good
	- Fair	- Mostly false	- Good
	- Poor	- Definitely false	- Fair
	- 1 001	- Definitely faise	- Poor
Concern for future health	J37	G20	L20
Concern for future health	Do you currently have	Do you currently have	Do you currently have
	anxieties/fears as a result of	anxieties/fears as a result of	
		your cancer, leukemia, tumor	anxieties/fears as a result of your cancer, leukemia, tumor or
	your cancer, leukemia, tumor or similar illness, or its		similar illness or its treatment?
	· · · · · · · · · · · · · · · · · · ·	or similar illness, or its	
	treatment?	treatment?	- No anxiety/fears
	- No anxiety/fears	- No anxiety/fears	- Small amount of anxiety/fears
	 Small amount of anxiety/fears Medium amount of 	- Small amount of	- Medium amount of
		anxiety/fears	anxiety/fears
	anxiety/fears	- Medium amount of	- A lot of anxiety/fears
	- A lot of anxiety/fears	anxiety/fears	- Very many, extreme
	- Very many, extreme	- A lot of anxiety/fears	anxiety/fears
	anxiety/fears	- Very many, extreme	
		anxiety/fears	
	DI	F12	01
	R1	F13	01
	How concerned are you about:	I expect my health to get	Please rate how concerned you
	Your future health	worse:	are about the following:
	- Very concerned	- Definitely true	Your future health
	- Somewhat concerned	- Mostly true	- Very concerned
	- Concerned	- Don't know	- Somewhat concerned
	- Not very concerned	- Mostly false	- Concerned
	 Not at all concerned 	- Definitely false	- Not very concerned
			- Not at all concerned
D1 1 1 1 1	N/4 4	a .	Nac
Physical health –	N14	G series	N26
Change in SF-12 summary	(SF12) Over the last 2 years,	Does your physical health now	Over the last 2 years, how long
score from baseline to FU(?)	how long (if at all) has your	limit you in these activities? If	(if at all) has your health limited
will be quantified.	health limited you in each of	so, how much?	you in each of the following
W 11 . OD	the following activities		activities?
We will examine means, SD,	- Not limited at all	- No, not limited	- Not limited at all
and standard errors of	- Limited for 3 months	- Yes limited a little	- Limited for 3 mos or <
measurement (SEM).	or less	 Yes limited a lot 	- Limited for > 3 mos
We	- Limited for more than	63	The late 1
We will use 1.96 SEMs to	3 months	G3	a. The kinds or amounts
determine 3 groups:	771 1 1	Vigorous activities, such	of vigorous activities
(1) Improved group =	a. The kinds or amounts	as running, lifting heavy	you can do, like lifting
Those who improved	of vigorous activities	objects, participating in	heavy objects, running
on their scores;	you can do, like lifting	strenuous sports	or participating in
(2) Decline group =	heavy objects, running		strenuous sports
Those who declined	or participating in	G4	b. The kinds or amounts
on their score;	strenuous sports	Moderate activities, such	of moderate activities
(3) No change group =	b. The kinds or amounts	as, moving a table,	you can do, like moving
Those with no change	of moderate activities	pushing a vacuum cleaner,	a table, carrying
Those with no change			
in their scores. ¹²	you can do, like	bowling, or playing golf	groceries or bowling
in their scores. ¹²			groceries or bowling c. Walking uphill or climbing a few flights

Table 4: Examples of predictor variables which will be used in the regression analysis for having an increased level of cancer-related care or for having a decreased level of cancer-related care utilization. In the analysis, we will evaluate the effect of the predictor variables as they change from Baseline to the last time point of follow-up using 2003 or 2007 data:

	bowling c. Walking uphill or climbing a few flights of stairs d. Bending lifting or stooping e. Walking one block f. Eating, dressing, bathing or using the toilet	Lifting or carrying groceries Climbing several flights of stairs Climbing one flight of stairs Bending, kneeling or stooping Walking more than one mile Walking several blocks Walking one block Bathing or dressing	of stairs d. Bending, lifting, or stooping e. Walking one block f. Eating, dressing, bathing, or using the toilet
.		yourself	7.01
Pain	J36 Do you currently have pain as a result of your cancer, leukemia, tumor or similar illness or its treatment? - No pain	G19 Do you currently have pain as a result of your cancer or similar illness, or its treatment? - No pain	L21 How much bodily pain have you had during the past 4 weeks?
	 Small amount of pain Medium amount of pain A lot of pain Very bad or excruciating pain 	 Small amount of pain Medium amount of pain A lot of pain Very bad, excruciating pain 	 Very mild Mild Moderate Severe Very severe
	No general bodily pain question	Bodily pain = E21	
Emotional health	J16-J35 BSI-18 Note: Scoring – Presents raw and normalized T scores for each of the three Primary Symptom Dimensions and the Global Severity Index. The plotted T scores are based on your choice of the community or oncology norms	G1-18 BSI-18 Note: Scoring – Presents raw and normalized T scores for each of the three Primary Symptom Dimensions and the Global Severity Index. The plotted T scores are based on your choice of the community or oncology norms	L1-18
Chronic disease status from baseline self-report questionnaire data (per Oeffinger's NEJM paper) ²			
Grade 0- 2 vs. Grades 3-4			
Define Grades 3-4 as: Having at least one grade 3(severe) or grade 4 (life- threatening or disabling) chronic condition			

Sample table 5 – Regression a	nalvses:	
Predictor Variables	Relative odds of	Relative odds of
	receiving higher level of	receiving a lower level
	care from Baseline to	of care from Baseline to
	last follow-up (using	last follow-up (using
	2003, 2007 data)	2003, 2007 data)
Age		
At time of questionnaire		
Age at diagnosis (mean)		
Gender		
Male		
Female		
Race/Ethnicity		
Non-Hispanic White (NHW)		
Black		
Hispanic		
Asian		
Other		
Health Insurance Status –	1	
Current vs. previous (in the		
baseline questionnaire may		
have had insurance with		
parents)		
No, U.S.		
Yes, U.S.		
Private		
Public (Medicaid/Medicare)		
None		
Canadian resident		
Current Annual household		
income		
<\$40,000		
\$40-79,000		
\$ 80,000 or greater		
Current Education		
< High school		
High school		
College graduate		
Employment status		
Employed or caring for home		
Looking for work or unable to		
work		
Student		
Overall Health Status		
Concern for future health		
Physical health		
Pain Emotional health		
Chronic disease status		
Mortality		
wortality		

	Relative odds of receiving higher level of care from Baseline to last fallow we (using 2002, 2007, data)	Relative odds of receiving lower level of care from Baseline to last
Radiation therapy	follow-up (using 2003, 2007 data)	follow-up (using 2003, 2007 data)
Brain		
Chest		
Not brain, not chest		
None		
RT status not known		
Cardiotoxic therapies		
Anthracyclines, no chest RT		
Chest RT, no anthracyclines		
Anthracyclines + chest RT		
No anthracyclines, no chest RT		
Alkylating agent dose		
None		
1 st tertile		
2 nd tertile		
3 rd tertile		

Sample Figure 1:

Percent of survivors with type of medical care by interval from cancer diagnosis



References:

³ Hewitt M, Weiner SL, Simone JV: Childhood Cancer Survivorship: Improving Care and Quality of Life. Washington, D.C., The National Academies Press, 2003

⁴ Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, and Robison LL. "Chronic Health Conditions in Adult Survivors of Childhood Cancer." N Engl J Med 355;15: 1572-1582, 2006.

⁵ Sklar CA: An overview of the effects of cancer therapies: the nature, scale, and breadth of the problem. Acta Paediatr Scan Suppl. 433:1-4, 1999

⁶ Mertens AC. "Cause of mortality in 5-year survivors of childhood cancer." Pediatr Blood Cancer. 2007 Jan 16; [Epub ahead of print]

⁷ Oeffinger KC, Mertens AC, Hudson MM, Gurney JG, Casillas J, Chen H, Whitton J, Yeazel M, Yasui Y, Robison LL. "Health care of young adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study." Ann Fam Med 2:61-70, 2004

⁸ Nathan PC, Greenberg ML, Ness KK, Hudson MH, Mertens AC, Mahoney MC, Gurney JG, Donaldson SS, Leisenring WM, Robison LL, Oeffinger KC: Medical Care in Long-Term Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study (CCSS). Journal of Clinical Oncology 2008: 26 (27): pp 4401-4409.

⁹ Landier W, Bhatia S, Eshelman DA, Forte KJ, Sweeney T, Hester AL, Darling J, Armstrong FD, Blatt J, Constine LS, Freeman CR, Friedman DL, Green DM, Marina N, Meadows AT, Neglia JP, Oeffinger KC, Robison LL, Ruccione KS, Sklar CA, Hudson MM. "Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology

12

¹ Reis LAG, Eisner MP, Kosary CL, et al: SEER Cancer Statistics Review, 1973-1998. National Cancer Institute, Bethesda, MD, 2001

² Mariotto AB, Cancer Epidemiol Biomarkers Prev. 2009

Group Late Effects Committee and Nursing Discipline." J Clin Oncol. 2004 Dec 15;22(24):4979-90. Epub 2004 Dec 2.

¹⁰ Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline.

Landier W, Bhatia S, Eshelman DA, Forte KJ, Sweeney T, Hester AL, Darling J, Armstrong FD, Blatt J,

Constine LS, Freeman CR, Friedman DL, Green DM, Marina N, Meadows AT, Neglia JP, Oeffinger KC,

Robison LL, Ruccione KS, Sklar CA, Hudson MM.

J Clin Oncol. 2004 Dec 15;22(24):4979-90. Epub 2004 Dec 2.

¹¹Oeffinger KC, Hudson MM, Mertens AC, Smith SM, Mitby PA, Eshelman-Kent DA, Ford JS, Jones JK,

Kamani S, Robison LL. Increasing rates of breast cancer and cardiac surveillance among high risk survivors of

childhood Hodgkin's lymphoma following a mailed, one-page survivorship care plan. Pediatric Blood and

Cancer, in press, 2010.

¹² Wolinsky FD, Wan GJ, Tierney WM. Changes in the SF-36 in 12 months in a clinical sample of

disadvantaged older adults. Med Care 1998; 36:1589-1598.